evidence: Using the search strategy, a total of 130 articles were found, of which five were relevant to the study, which were included in the study [Figure 1]. Of the five studies, three were from India (two case series and one cross-sectional), one was from Brazil (case study), and one was from Singapore (case study). Descriptive statistics were used to summarize the characteristics of the included studies [Table 2]. A total of 11 people affected with leprosy-acquired adverse events after the administration of the Covid-19 vaccine were identified from these studies. The adverse reactions were acquired mostly in males [9 (81.8%)], and the majority of them belong to borderline tuberculoid (BT) [4 (36.4%)], borderline lepromatous (BL) [4 (36.4%)], and lepromatous leprosy (LL) [3 (27.3%)]. Most of the patients were released from treatment (MDT) [7 (63.6%)], and 2 (18.2%) were newly identified after vaccination. In the context of Covid-19 vaccination, 4 (45.5%) were vaccinated with ChAdOx1 nCoV-19 vaccine, 4 (36.4%) were immunized with Covaxin, and the remaining were vaccinated with Covishield and Pfizer-BioNTech Covid-19 vaccination. [...] Google Scholar 13. Bhandari A, Shilpa, Gupta S, Dogra S, Narang T. Reactions in leprosy patients triggered by COVID-19 vaccination - a cross-sectional study from a tertiary care centre in India. J Eur Acad Dermatol Venereol 2022;36:e971–2.